Sanofi SA ADR
SNY: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$36.00 | Cwbr | Rxwtkhjm |
Sanofi's Diverse Product Portfolio Remains Well Positioned for Steady Gains
Business Strategy and Outlook
Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset upcoming patent losses.